Level Four Advisory Services’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$656K Buy
3,471
+7
+0.2% +$1.22K 0.02% 517
2025
Q4
$589K Buy
3,464
+4
+0.1% +$613 0.02% 529
2025
Q3
$456K Hold
3,460
0.02% 580
2025
Q2
$367K Buy
+3,460
New +$376K 0.01% 597
2017
Q4
Sell
-4,145
Closed -$606K 552
2017
Q3
$606K Buy
4,145
+2,459
+146% +$372K 0.05% 311
2017
Q2
$237K Sell
1,686
-1,043
-38% -$159K 0.04% 428
2017
Q1
$389K Buy
2,729
+23
+0.8% +$3K 0.04% 358
2016
Q4
$295K Buy
+2,706
New +$301K 0.04% 366

Other funds holding JAZZ

Level Four Advisory Services's JAZZ Position: Q1 2026 in Review

Level Four Advisory Services increased its Jazz Pharmaceuticals (JAZZ) stake by 0.2% in Q1 2026, buying an estimated $1.22K and bringing the position to 3,471 shares worth $656K. The position accounts for 0.02% of the portfolio, ranked #517.

Level Four Advisory Services first reported a position in JAZZ in Q4 2016 and has held it in 8 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Level Four Advisory Services held 3,471 shares of Jazz Pharmaceuticals worth $656K as of Q1 2026.
  • Level Four Advisory Services bought 7 Jazz Pharmaceuticals shares in Q1 2026, an estimated $1.22K.
  • Jazz Pharmaceuticals made up 0.02% of Level Four Advisory Services's portfolio in Q1 2026, its #517 holding.
  • Level Four Advisory Services first reported a position in Jazz Pharmaceuticals in Q4 2016 and has held it in 8 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Level Four Advisory Services's 13F filing for Q1 2026, filed 14 May 2026.